NYSE:SCR - Simcere Pharmaceutical Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7,460.00 +10.00 (+0.13 %)
(As of 02/22/2019 04:00 PM ET)
Previous Close$7,460.00
Today's Range$7,420.00 - $7,510.00
52-Week RangeN/A
Volume1.59 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Simcere Pharmaceutical Group (Simcere) is a holding company. The Company principally engaged in the research, development, manufacture and distribution of pharmaceutical and vaccine products in the People's Republic of China. Company markets and sells its products directly or indirectly to approximately 1,405 pharmaceutical distributors who in turn sell these products to other distributors, hospitals and retail pharmacies throughout China. As of March 31, 2013, the Company also had over 11 product candidates in various stages of development, including treatments for cancer and cardiovascular diseases. In December 2013, Simcere completed the merger contemplated by the previously announced Agreement and Plan of Merger among the Company, Simcere Holding Limited (Parent) and Simcere Acquisition Limited (Merger Sub), and as a result of the merger, the Company became a wholly owned subsidiary of Parent.

Receive SCR News and Ratings via Email

Sign-up to receive the latest news and ratings for SCR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
CUSIPN/A
Phone+86-25-85566666

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Simcere Pharmaceutical Group (NYSE:SCR) Frequently Asked Questions

What is Simcere Pharmaceutical Group's stock symbol?

Simcere Pharmaceutical Group trades on the New York Stock Exchange (NYSE) under the ticker symbol "SCR."

Has Simcere Pharmaceutical Group been receiving favorable news coverage?

News headlines about SCR stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Simcere Pharmaceutical Group earned a daily sentiment score of -1.5 on InfoTrie's scale. They also gave news headlines about the healthcare company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days.

How do I buy shares of Simcere Pharmaceutical Group?

Shares of SCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Simcere Pharmaceutical Group's stock price today?

One share of SCR stock can currently be purchased for approximately $7,460.00.

What is Simcere Pharmaceutical Group's official website?

The official website for Simcere Pharmaceutical Group is http://www.simcere.com.

How can I contact Simcere Pharmaceutical Group?

Simcere Pharmaceutical Group's mailing address is No.699-18 Xuan Wu Avenue Xuan Wu District, NANJING, JNG 210042, China. The healthcare company can be reached via phone at +86-25-85566666.


MarketBeat Community Rating for Simcere Pharmaceutical Group (NYSE SCR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about Simcere Pharmaceutical Group and other stocks. Vote "Outperform" if you believe SCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel